Precise Bio has filed a notice of an exempt offering of securities to raise $25,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Precise Bio is raising up to $25,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Eyal Arieli played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Precise Bio
Precise Bio develops and commercializes 4D bio-fabricated functional tissues and organs that can save lives and improve its quality. We combine world-class tissue-engineering and transplantation experience with best-in-class bio-printing, to create a scalable bio-fabrication platform, that can overcome current industry challenges and make complex human organs available for transplantation.
To learn more about Precise Bio, visit http://www.precise-bio.com/
Contact:
Eyal Arieli, Chief Financial Officer
336-955-1120
https://www.linkedin.com/in/eyal-arieli-b88791a/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.